Panel Discussion: Positioning Novel Mechanisms in the Myasthenia Gravis Market to Deliver Differentiated Patient Benefit
9:00 am - Wednesday 22nd July 2026
- Comparing how FcRn inhibition, complement blockade, B-cell depletion and CAR-T differ mechanistically and where each may sit best based on disease biology
- Examining how mechanistic sequencing could address patients exposed to prior lines of therapy without clear biomarkerguidance
- Identifying emerging strategies for treating MG patients who fail FcRn inhibition, IgG degraders or complement therapies
- Gain insight into how to position assets in a saturated market while addressing inadequate responders and future curative ambition
